Observational studyGeriatrics & gerontology international2026
Prognostic Utility of the Total Body Muscle Mass in Heart Failure: Insights From the JEDI-AHF Registry.
Observational study in Geriatrics & gerontology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Total Body Muscle Mass in Heart Failure: A Marker of Muscle Loss or Systemic Vulnerability?Geriatrics & gerontology international · 2026Article
- Beyond Muscle Mass: Interpreting TBMM as a Marker of Geriatric Vulnerability in Acute Heart Failure.Geriatrics & gerontology international · 2026Article
- Beyond Total Body Muscle Mass: The Necessity of Incorporating Muscle Function for Risk Stratification in Heart Failure.Geriatrics & gerontology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
aimQuantifying skeletal muscle mass is essential for patients with heart failure; however, common modalities, such as bioelectrical impedance analysis, can be distorted by fluid retention. The total body muscle mass (TBMM), a creatinine-cystatin C-derived marker, has been proposed as a practical blood-based surrogate of muscle mass; however, its relationship with muscle mass and its prognostic value in acute heart failure remain uncertain. Therefore, we aimed to assess whether TBMM is associated with skeletal muscle mass indices in heart failure and postdischarge all-cause mortality in patients hospitalized for acute heart failure.
methodsThis single-center retrospective study included patients hospitalized for acute heart failure at Juntendo University Hospital (January 2015-December 2021). TBMM was calculated from body weight, serum creatinine, and cystatin C, and classified using prespecified sex-specific cut-offs (men, < 38.846; women, < 26.476).
resultsAmong the 550 patients, 271 had low TBMM. Over a median follow-up of 2.6 years, 134 deaths occurred (low-TBMM, 79; high-TBMM, 55). Patients with low TBMM showed significantly lower survival and a higher risk of postdischarge mortality after adjustment. Findings were consistent across the left ventricular ejection fraction strata (< 50% and ≥ 50%). TBMM correlated strongly with appendicular skeletal muscle mass index, estimated using both anthropometric and biomarker-based models.
conclusionsIn patients hospitalized for acute heart failure, TBMM was strongly correlated with estimated muscle mass and independently associated with postdischarge all-cause mortality. Therefore, TBMM may complement routine risk stratification and help identify patients with heightened vulnerability related to muscle impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.